Assessment of endpoints for clinical trials for localized prostate cancer
Open Access
- 1 April 1997
- Vol. 49 (4), 27-38
- https://doi.org/10.1016/s0090-4295(99)80321-5
Abstract
No abstract availableThis publication has 68 references indexed in Scilit:
- Mortality in Prostate CancerJournal of Urology, 1996
- Suramin-Induced Decrease in Prostate-Specific Antigen Expression With No Effect on Tumor Growth in the LNCaP Model of Human Prostate CancerJNCI Journal of the National Cancer Institute, 1996
- How Much Can We Rely on the Level of Prostate-Specific Antigen as an End Point for Evaluation of Clinical Trials? A Word of Caution!JNCI Journal of the National Cancer Institute, 1996
- Cancer statistics, 1996CA: A Cancer Journal for Clinicians, 1996
- The Incidence of Prostate Cancer Progression with Undetectable Serum Prostate Specific Antigen in a Series of 394 Radical ProstatectomiesJournal of Urology, 1995
- Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer: Prognostic implicationsInternational Journal of Radiation Oncology*Biology*Physics, 1994
- Surrogate markers in aids and cancer trialsStatistics in Medicine, 1994
- Noncancer Deaths in White Adult Cancer PatientsJNCI Journal of the National Cancer Institute, 1993
- Preliminary Report: Effect of Encainide and Flecainide on Mortality in a Randomized Trial of Arrhythmia Suppression after Myocardial InfarctionNew England Journal of Medicine, 1989
- Quality of Life End Points in Cancer Clinical Trials: Review and RecommendationsJNCI Journal of the National Cancer Institute, 1989